ATX Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Returns
| 1 day | -4.3% |
| 1 week | -8.3% |
| 1 month | -18.5% |
| 3 months | -26.7% |
| 6 months | -35.3% |
| 1 year | -37.1% |
| 3 years | 31.0% |
Risk
| Volatility (1y ann.) | 147.9% |
| Beta vs ASX 200 | 0.49 |
| Sharpe (1y) | 0.24 |
| VaR 95% (1-day) | -8.8% |
| Max drawdown (1y) | -60.4% |
| Off 1-year high | -58.5% |
Technicals
| RSI(14) | 25 OS |
| vs 50DMA | -17.8% |
| vs 200DMA | -21.5% |
| Trend | Death cross |
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
- Revenue—
- Gross profit—
- Operating income-$13.18M
- Net income-$7.71M
- Diluted EPS-0.02
- Free cash flow-$8.77M
- Net debt-$27.51M